Ansamycin: Difference between revisions

Jump to navigation Jump to search
m (Protected "Ansamycin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
Line 1: Line 1:
{{SI}}
{{SI}}
{{EH}}
 


'''Ansamycins''' is a family of secondary metabolites that show antimicrobial activity against many gram-positive and some gram-negative bacteria and includes various compounds among which: streptovaricins and rifamycins <ref>{{cite journal |author=Wehrli, W.; Staehelin, M. |journal=Bacteriol. Rev. |title=Actions of the rifamycins |volume=35 |pages=290 |year=1971}}</ref>.  In addition, these compounds demonstrated antiviral activity towards bacteriophages and poxviruses.  They are named ansamycins—''ansa'' from the Latin for handle—because of their unique structure which comprises an aromatic moiety bridged by an aliphatic chain <ref>{{cite journal |author=Prelog, V.; Oppolzer, W. |journal=Helv. Chim. Acta. |title=Rifamycins. 4. Ansamycins, a novel class of microbial metabolism products |volume=56 |pages=2279 |year=1973}}</ref>.  The main difference between various derivatives of ansamycins is the aromatic moiety, which can be a naphthalene ring or a naphthoquinone ring as in rifamycin and naphthomycin <ref>{{cite journal |author=Balerna, M.; Keller-Schierlein, W.; Martius, C.; Wolf, H.; Zähner, H. |journal=Arch. Mikrobiol. |title=Metabolic products of microorganisms. 72. Naphthomycin, an antimetabolite of vitamin K |volume=65 |pages=303 |year=1969}}</ref>.
'''Ansamycins''' is a family of secondary metabolites that show antimicrobial activity against many gram-positive and some gram-negative bacteria and includes various compounds among which: streptovaricins and rifamycins <ref>{{cite journal |author=Wehrli, W.; Staehelin, M. |journal=Bacteriol. Rev. |title=Actions of the rifamycins |volume=35 |pages=290 |year=1971}}</ref>.  In addition, these compounds demonstrated antiviral activity towards bacteriophages and poxviruses.  They are named ansamycins—''ansa'' from the Latin for handle—because of their unique structure which comprises an aromatic moiety bridged by an aliphatic chain <ref>{{cite journal |author=Prelog, V.; Oppolzer, W. |journal=Helv. Chim. Acta. |title=Rifamycins. 4. Ansamycins, a novel class of microbial metabolism products |volume=56 |pages=2279 |year=1973}}</ref>.  The main difference between various derivatives of ansamycins is the aromatic moiety, which can be a naphthalene ring or a naphthoquinone ring as in rifamycin and naphthomycin <ref>{{cite journal |author=Balerna, M.; Keller-Schierlein, W.; Martius, C.; Wolf, H.; Zähner, H. |journal=Arch. Mikrobiol. |title=Metabolic products of microorganisms. 72. Naphthomycin, an antimetabolite of vitamin K |volume=65 |pages=303 |year=1969}}</ref>.
Line 11: Line 11:
[[Category: antibiotics]]
[[Category: antibiotics]]


{{SIB}}
 


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WS}}
{{WS}}

Latest revision as of 22:15, 8 August 2012

WikiDoc Resources for Ansamycin

Articles

Most recent articles on Ansamycin

Most cited articles on Ansamycin

Review articles on Ansamycin

Articles on Ansamycin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ansamycin

Images of Ansamycin

Photos of Ansamycin

Podcasts & MP3s on Ansamycin

Videos on Ansamycin

Evidence Based Medicine

Cochrane Collaboration on Ansamycin

Bandolier on Ansamycin

TRIP on Ansamycin

Clinical Trials

Ongoing Trials on Ansamycin at Clinical Trials.gov

Trial results on Ansamycin

Clinical Trials on Ansamycin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ansamycin

NICE Guidance on Ansamycin

NHS PRODIGY Guidance

FDA on Ansamycin

CDC on Ansamycin

Books

Books on Ansamycin

News

Ansamycin in the news

Be alerted to news on Ansamycin

News trends on Ansamycin

Commentary

Blogs on Ansamycin

Definitions

Definitions of Ansamycin

Patient Resources / Community

Patient resources on Ansamycin

Discussion groups on Ansamycin

Patient Handouts on Ansamycin

Directions to Hospitals Treating Ansamycin

Risk calculators and risk factors for Ansamycin

Healthcare Provider Resources

Symptoms of Ansamycin

Causes & Risk Factors for Ansamycin

Diagnostic studies for Ansamycin

Treatment of Ansamycin

Continuing Medical Education (CME)

CME Programs on Ansamycin

International

Ansamycin en Espanol

Ansamycin en Francais

Business

Ansamycin in the Marketplace

Patents on Ansamycin

Experimental / Informatics

List of terms related to Ansamycin


Ansamycins is a family of secondary metabolites that show antimicrobial activity against many gram-positive and some gram-negative bacteria and includes various compounds among which: streptovaricins and rifamycins [1]. In addition, these compounds demonstrated antiviral activity towards bacteriophages and poxviruses. They are named ansamycins—ansa from the Latin for handle—because of their unique structure which comprises an aromatic moiety bridged by an aliphatic chain [2]. The main difference between various derivatives of ansamycins is the aromatic moiety, which can be a naphthalene ring or a naphthoquinone ring as in rifamycin and naphthomycin [3]. Another variation comprises benzene or a benzoquinone ring system as in geldanamycin or ansamitocin. Ansamycins were first discovered in 1959 by Sensi et al from Amycolatopsis mediterranei, an Actinomycete.[4] Rifamycins are a subclass of ansamycins with high potency against mycobacterial activity. This resulted in their wide use in the treatment of tuberculosis, leprosy, and AIDS-related mycobacterial infections.[5] Since then various analogues have been isolated from other prokaryotes.

References

  1. Wehrli, W.; Staehelin, M. (1971). "Actions of the rifamycins". Bacteriol. Rev. 35: 290.
  2. Prelog, V.; Oppolzer, W. (1973). "Rifamycins. 4. Ansamycins, a novel class of microbial metabolism products". Helv. Chim. Acta. 56: 2279.
  3. Balerna, M.; Keller-Schierlein, W.; Martius, C.; Wolf, H.; Zähner, H. (1969). "Metabolic products of microorganisms. 72. Naphthomycin, an antimetabolite of vitamin K". Arch. Mikrobiol. 65: 303.
  4. Sensi, P.; Margalith, P.; Timbal, M. T. (1959). "Rifomycin, a new antibiotic; preliminary report". Ed. Sci. 14: 146.
  5. Floss, H. G.; Yu, T. (1999). "Lessons from the rifamycin biosynthetic gene cluster". Curr. Opin. Chem. Biol. 3: 592.



Template:WS